Mind-motor Exercise to Improve Cognition and Functional Fitness

Overview

This is a 3 month cluster randomized controlled trial using a square-stepping exercise program (a.k.a. mind-motor exercise) in retirement and long-term care residences to improve global cognitive functioning in older adults with and without cognitive impairments. The investigators intend this project to be pragmatic and therefore will include residents with dementia and walking aids if the participants wish to participate. The primary outcome is global cognitive functioning, secondary outcomes include: single and dual task gait (only completed with those without dementia), oculomotor functioning, and functional fitness. The investigators hypothesize that there will be improvements in primary and secondary outcomes in the intervention group.

Full Title of Study: “The MIND-FUN Research Study: Mind-motor Exercise to Improve Cognition and Functional Fitness”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2016

Detailed Description

Square Stepping Exercise (SSE) can be best described as a visuospatial working memory task, with a stepping response and thus may be considered as a cognitive-physical exercise or alternatively as a type of mind-motor exercise. The SSE program was developed specifically to improve balance and lower extremity functioning and thereby prevent disability and institutionalization in older adults with recent evidence also suggesting that it may positively impact cognitive functioning. Through the investigators' collaboration with Dr. Mike Sharratt, President of the Schlegel-University of Waterloo Research Institute for Aging, Jaimie Killingbeck, Program for Active Living Coordinator for Schlegel Villages, and Susan Brown, Research Coordinator for the Schlegel-University of Waterloo Research Institute for Aging this study aims to: further assess the feasibility of square-stepping exercise amongst older adults with a variety of cognitive abilities, increase our collaborative efforts in the broader community and to engage older adults in physical activity to improve global cognitive functioning through a mind-motor exercise intervention. This study will be a cluster randomized controlled trial, stratified by long-term care or full continuum care of the 4 Schlegel Villages involved, not blinded. The investigators will stratify so that 1 long-term care and 1 full continuum will be randomized to begin the square-stepping program immediately, and 1 long-term care and 1 full continuum care will be randomized to usual-care wait list control group, that will begin the program once 12-week measurements are complete. The facilities were stratified to help balance baseline cognition between the intervention and control groups. The 4 facilities are: Long-term Care – Glendale Crossings and St. Claire; Full continuum Care – Tansley Woods and Winston Park. The sites were pre-randomized to allow facilities time to prepare their programming schedules to include square-stepping exercise to their residents. Intervention sites include Glendale Crossings and Tansley Woods and wait-list control sites include St. Claire and Winston Park. Outcomes assessments will be completed by graduate students and research assistants on this project. The assessments will be completed at each of the Villages. The Schlegel Villages staff Kinesiologists/ Exercise Therapists will implement the square-stepping exercise program during the 12 week period. Study staff will train the Schlegel Villages staff on how to implement the program.

Interventions

  • Behavioral: Square Stepping Exercise
    • Square Stepping Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids. In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged.

Arms, Groups and Cohorts

  • Experimental: Square Stepping Exercise
    • Square-Stepping Exercise (SSE) Intervention Participants in this group will attend a square-stepping exercise intervention 60 minutes: 5 minute for attendance, 5-10 minute warm-up 40-45 minute SSE and 5-10 minute cool-down, on two days a week for a duration of 12 weeks.
  • No Intervention: Usual-care wait-list control
    • This group will receive standard care and be invited to partake in the intervention after all assessments have been completed.

Clinical Trial Outcome Measures

Primary Measures

  • Composite score from Cambridge Brain Sciences Cognitive Battery
    • Time Frame: Change from 0 to 12 weeks
    • To assess global cognitive function.

Secondary Measures

  • Gait variability (stride time) under dual-task conditions
    • Time Frame: Change from 0 to 12 weeks
    • Gait variability is the stride-to-stride fluctuations of the way someone walks and will be calculated as the coefficient of variation of step length (SD/mean x100). Measured with GAITRite system.
  • Gait variability (stride time) under single-task conditions
    • Time Frame: Change from 0 to 12 weeks
    • Gait variability is the stride-to-stride fluctuations of the way someone walks and will be calculated as the coefficient of variation of step length (SD/mean x100). Measured with GAITRite system (portable gait analysis).
  • Gait velocity (speed) under dual-task conditions
    • Time Frame: Change from 0 to 12 weeks
    • Average walking speed (gait velocity) measured with the GAITRite system (portable gait analysis)
  • Gait velocity (speed) under single-task conditions
    • Time Frame: Change from 0 to 12 weeks
    • Average walking speed (gait velocity) measured with the GAITRite system (portable gait analysis).
  • Step length (average) under dual-task conditions
    • Time Frame: Change from 0 to 12 weeks
    • Mean step length calculated from GAITRite system (portable gait analysis).
  • Step length (average) under single-task conditions
    • Time Frame: Change from 0 to 12 weeks
    • Mean step length calculated from GAITRite system (portable gait analysis).
  • Memory composite score
    • Time Frame: Change from 0 to 12 weeks
    • Measured by Cambridge Brain Sciences – composite score from 4 memory tasks
  • Reasoning composite score
    • Time Frame: Change from 0 to 12 weeks
    • Measured by Cambridge Brain Sciences – composite score from 3 reasoning tasks
  • Concentration composite score
    • Time Frame: Change from 0 to 12 weeks
    • Measured by Cambridge Brain Sciences – composite score from 3 concentration tasks
  • Planning (executive functioning) composite score
    • Time Frame: Change from 0 to 12 weeks
    • Measured by Cambridge Brain Sciences – composite score from 2 planning (executive function) tasks
  • Short Performance Physical Battery – Balance
    • Time Frame: Change from 0 to 12 weeks
    • To assess balance measured by Side by Side Stand, Semi-Tandem Stand, Tandem Stand to obtain a balance test score.
  • Neuropsychiatric Inventory Questionnaire
    • Time Frame: change from 0 to 12 weeks
    • To assess behavioural changes in residents with dementia

Participating in This Clinical Trial

Inclusion Criteria

  • All residents of the 4 Schlegel Villages: Glendale Crossing, St. Clair, Tansley Woods, Winston Park – Both males and females Exclusion Criteria:

  • Wheelchair bound residents – Residents who are blind or deaf without aids – Any residents who may not be able to participate due to health or behaviours in collaboration and discretion of the Schlegel Villages staff. – Residents who have a diagnosis of dementia, have a score of greater than 3 on the Cognitive Performance Scale (determined by each Schlegel Village) and advice from Schlegel Villages staff will be excluded from specific assessments (dual-task gait; oculomotor function; global cognitive functioning outcomes; Montreal Cognitive Assessment; 2 cognitive questions).

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Western Ontario, Canada
  • Collaborator
    • Schlegel Villages: Retirement Homes and Long Term Care
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Robert Petrella, MD, PhD, Principal Investigator, Western University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.